Angiomax (bivalirudin)
Phase 3Small molecule
NovartisAngiomax (bivalirudin) is one of 99 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
98
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
216 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Adenocard
AstellasPhase 3
Lovenox
SanofiPhase 3
Lovenox
SanofiPhase 3
Aldactone
PfizerPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Glucophage
EMD SeronoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Rayaldee
OOrganon and Co
Phase 3
Allegra
CChattem
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Coronary Artery Bypass1 trial
Acute Coronary Syndrome1 trial
Acute Myocardial Infarction1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Angiomax (bivalirudin). EMBL-EBI & Wellcome Sanger Institute.
- [4]